56 related articles for article (PubMed ID: 38502281)
1. Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study.
Gomes F; Khatoon B; Sawyer C; Punnett G; Farrington N; Yorke J
J Geriatr Oncol; 2024 Jun; 15(5):101777. PubMed ID: 38704912
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life Is Independently Associated With Neurocognitive Function in Patients With Brain Tumors: Analysis of a Prospective Clinical Trial.
Salans M; Tibbs MD; Huynh-Le MP; Yip A; Tringale K; Karunamuni R; Xu R; Reyes A; Macari AC; Pan-Weisz T; McDonald CR; Hattangadi-Gluth JA
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):754-763. PubMed ID: 34102297
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.
Caramanna I; Klein M; van den Bent M; Idbaih A; Wick W; Taphoorn MJB; Dirven L; Bottomley A; Reijneveld JC;
Qual Life Res; 2022 Nov; 31(11):3253-3266. PubMed ID: 35982202
[TBL] [Abstract][Full Text] [Related]
4. Exercise interventions on health-related quality of life for people with cancer during active treatment.
Mishra SI; Scherer RW; Snyder C; Geigle PM; Berlanstein DR; Topaloglu O
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD008465. PubMed ID: 22895974
[TBL] [Abstract][Full Text] [Related]
5. Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.
Buergy D; Schneiberg V; Schaefer J; Welzel G; Trojan L; Bolenz C; Wenz F
Health Qual Life Outcomes; 2018 Jan; 16(1):21. PubMed ID: 29357874
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
[TBL] [Abstract][Full Text] [Related]
7. Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy.
van der Meer PB; Habets EJJ; Wiggenraad RG; Verbeek-de Kanter A; Lycklama À Nijeholt GJ; Zwinkels H; Klein M; Dirven L; Taphoorn MJB
J Neurooncol; 2018 Sep; 139(2):359-368. PubMed ID: 29663172
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).
Wefel JS; Armstrong TS; Pugh SL; Gilbert MR; Wendland MM; Brachman DG; Roof KS; Brown PD; Crocker IR; Robins HI; Hunter G; Won M; Mehta MP
Neuro Oncol; 2021 Jul; 23(7):1125-1138. PubMed ID: 33515019
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.
Rogiers A; Leys C; Lauwyck J; Schembri A; Awada G; Schwarze JK; De Cremer J; Theuns P; Maruff P; De Ridder M; Bernheim JL; Neyns B
J Immunol Res; 2020; 2020():2192480. PubMed ID: 32775464
[TBL] [Abstract][Full Text] [Related]
10. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
11. Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.
Van Der Weijst L; Surmont V; Schrauwen W; Lievens Y
Front Oncol; 2021; 11():685605. PubMed ID: 34222010
[TBL] [Abstract][Full Text] [Related]
12. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
13. Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial.
Field KM; Barnes EH; Sim HW; Nowak AK; Simes J; Rosenthal MA; Wheeler H; Hovey EJ; Cher LM
J Clin Neurosci; 2021 Dec; 94():321-327. PubMed ID: 34863458
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
[TBL] [Abstract][Full Text] [Related]
15. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J; Schwarze JK; Awada G; Tijtgat J; Vaeyens F; Bertels C; Geens W; Klein S; Seynaeve L; Cras L; D'Haene N; Michotte A; Caljon B; Salmon I; Bruneau M; Kockx M; Van Dooren S; Vanbinst AM; Everaert H; Forsyth R; Neyns B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168003
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
